ANI Pharmaceuticals Inc (ANIP, Financial), a pharmaceutical company engaged in the development, manufacturing, and marketing of specialized branded and generic drugs, has reported an insider sale according to a recent SEC filing. Director Antonio Pera sold 7,000 shares of the company on March 4, 2024.
Antonio Pera’s transaction involved the disposal of 7,000 shares at a price point that has not been disclosed in the summary provided. Over the past year, the insider has sold a total of 10,000 shares and has not made any share purchases.
The insider transaction history for ANI Pharmaceuticals Inc (ANIP) indicates a pattern of insider sales with 34 recorded over the past year and no insider buys during the same period.
On the valuation front, ANI Pharmaceuticals Inc (ANIP) shares were trading at $65.2 each on the day of the insider's recent sale, resulting in a market capitalization of $1.344 billion. The price-earnings ratio stands at 80.26, which is above both the industry median of 22.74 and the company's historical median.
Considering the current share price and the GuruFocus Value of $56.57, ANI Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.15, suggesting that the stock is modestly overvalued. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
The recent insider sale by Director Antonio Pera may provide investors with insight into the insider's perspective on the company's valuation and future prospects. However, investors are encouraged to consider the broader context of insider transactions, the company's performance, and market conditions when evaluating the significance of this sale.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
